A duel treatment pill for enlarged prostate patients has been approved for use in the UK.
Marketed as Combodart by GlaxoSmithKline, it is the first fixed dose combination therapy for treatment of benign prostatic hyperplasia.
It contains dutasteride 0.5mg and tamsulosin hydrochloride 0.4mg. Dutasteride delays progression of the disease by inhibiting the production of the male hormone dihydrotestosterone (DHT) that stimulates prostate growth, whilst tamsulosin provides symptom relief by reducing smooth muscle tone in the prostate and bladder neck.
Dr Jon Rees, a Bristol GP with a special interest in urology, said: “By combining the medication that targets the underlying cause of the disease with one that relieves symptoms fairly quickly, patients will be more likely to keep taking their medication, which in turn will decrease the risk of disease progression or patients requiring emergency surgery.”